Physician profile
Toni D Vu
NPI 1851402358
$4,327.92
in general payments reported to CMS, 2019-2025
35 companies · $731 in 2025
The $731 reported for 2025 was more than what 87% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,214 · 2020: $203 · 2021: $618 · 2022: $570 · 2023: $626 · 2024: $364 · 2025: $731.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,703 · Education: $19.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,702.58 |
| Education | $19.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $775.49 | 2019-2025 | Lo Loestrin Fe, Orilissa |
| Coloplast Corp | $774.59 | 2019 | |
| Pfizer INC. | $450.11 | 2021-2024 | |
| Mayne Pharma Commercial LLC | $259.34 | 2022-2025 | |
| Duchesnay USA Incorporated | $197.85 | 2019 | |
| Aspira Women'S Health INC | $195.97 | 2020-2024 | Ova1 |
| Sage Therapeutics, LLC | $143.78 | 2024-2025 | Zurzuvae |
| Exeltis, USA INC. | $123.57 | 2019-2025 | Slynd, Tyblume |
| Bayer Healthcare Pharmaceuticals INC. | $122.69 | 2020-2025 | |
| Therapeuticsmd, INC. | $111.44 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $105.84 | 2023-2025 | Myfembree |
| Astellas Pharma US INC | $101.79 | 2023-2025 | Veozah |
| Myovant Sciences INC. | $100.73 | 2021-2022 | |
| Minerva Surgical, INC | $85.24 | 2019-2025 | |
| Millicent US INC | $71.25 | 2024-2025 | Intrarosa, Femring |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $65.08 | 2021-2025 | Bulkamid |
| Amag Pharmaceuticals, INC. | $63.44 | 2019-2020 | |
| Organon LLC | $54.14 | 2021-2024 | |
| Shield Therapeutics INC | $52.86 | 2023 | Accrufer |
| Avion Pharmaceuticals | $52.57 | 2021-2022 | |
| Smith+Nephew, INC. | $49.07 | 2024-2025 | Stravix, Pico 14 |
| Agile Therapeutics, INC. | $42.66 | 2023 | Twirla |
| Cepheid | $41.31 | 2025 | Genexpert |
| Dexcom, INC. | $40.16 | 2025 | Dexcom G6 Transmitter |
| Lupin INC. | $38.36 | 2019-2020 | |
| Mylan Pharmaceuticals INC. | $38.27 | 2019-2022 | |
| Hologic Sales and Service, LLC | $36.77 | 2019-2025 | Thinprep 2000 Processor |
| Vertex Pharmaceuticals Incorporated | $27.43 | 2024 | |
| Allergan, INC. | $18.04 | 2019 | |
| Scynexis, INC. | $15.99 | 2022 | |
| Evofem Biosciences, INC. | $15.79 | 2022 | |
| Merck Sharp & Dohme LLC | $15.33 | 2019 | |
| Coopersurgical, INC. | $14.44 | 2023 | Paragard T 380a |
| Meditrina | $13.32 | 2022 | |
| Dysis Medical, INC. | $13.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Toni Vu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.